Novocure Share Price Today
(NASDAQ: NVCR)

Name: Novocure Share Price Today (NASDAQ: NVCR) - Novocure Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Novocure share price is $24.52 & ₹2,124.41 as on 1 Feb 2025, 2.30 'hrs' IST

$24.52

▲

-0.99

(-3.88%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Novocure share price in Dollar and Rupees. Guide to invest in Novocure stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Novocure, along with analyst recommendations, forecasts, and comprehensive financials.

Novocure share price movements

Today's Low: $24.33
Today's High: $25.79
$24.52
0.77%
Downside
Day's Volatility :5.66%
Upside
4.92%
52 Weeks Low: $11.70
52 Weeks High: $34.13
$24.52
52.28%
Downside
52 Weeks Volatility :65.72%
Upside
28.16%

Novocure (NVCR) Returns

Period	Novocure Limited	Sector (Health Care)	Index (Russel 2000)
3 Months	47.8%	-0.6%	0.0%
6 Months	19.73%	-2.8%	0.0%
1 Year	73.9%	3.3%	0.0%
3 Years	-66.75%	11.6%	-13.7%

Novocure (NVCR) Key Statistics

in dollars & INR

Previous Close	$25.51
Open	$25.69
Today's High	$25.79
Today's Low	$24.33
Market Capitalization	$2.8B
Today's Volume	$683.1K
52 Week High	$34.13
52 Week Low	$11.7
Revenue TTM	$577.7M
EBITDA	$-140.6M
Earnings Per Share (EPS)	$-1.39
Profit Margin	-25.93%
Quarterly Earnings Growth YOY	-0.06%
Return On Equity TTM	-39.71%

How to invest in Novocure Stock (NVCR) from India?

It is very easy for Indian residents to invest directly in Novocure from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Novocure stock in both Indian Rupees (INR) and US Dollars (USD). Search for Novocure or NVCR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Novocure or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Novocure shares which would translate to 0.035 fractional shares of Novocure as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Novocure, in just a few clicks!

Returns in Novocure (NVCR) for Indian investors in Rupees

The Novocure stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Novocure investment value today

Current value as on today

₹1,78,460

Returns

₹78,460

(+78.46%)

Returns from Novocure Stock

₹73,901 (+73.9%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Novocure (NVCR)

-62.71%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Investment in Novocure Shares from India has dropped by -62.71% over the past 30 days, indicating reduced transactional activity.

-73%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Novocure Stock from India on INDmoney has decreased by -73% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Novocure

FMR Inc
15.00%
BlackRock Inc
11.81%
Vanguard Group Inc
10.95%
Capital Research & Mgmt Co - Division 3
7.32%
Capital World Investors
3.98%
Nordwand Advisors LLC
2.80%

Analyst Recommendation on Novocure

Buy

61%Buy

38%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Novocure(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Novocure Stock (NVCR)

What analysts predicted

Upside of 46.14%

Target:

$35.83

Current:

$24.52

Insights on Novocure Stock (Ticker Symbol: NVCR)

Price Movement
In the last 1 month, NVCR stock has moved down by -17.7%
Increasing Revenue
Revenue is up for the last 7 quarters, 122.18M → 155.09M (in $), with an average increase of 3.9% per quarter
Increasing Net Profit
Netprofit is up for the last 6 quarters, -57.41M → -30.57M (in $), with an average increase of 13.6% per quarter
NVCR vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 135.3% return, outperforming this stock by 201.1%

NVCR Novocure Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$248.1M	↑ 40.13%
Net Income	$-63.6M	↑ 3.08%
Net Profit Margin	-25.62%	↑ 9.21%

	FY19	Y/Y Change
Revenue	$351.3M	↑ 41.62%
Net Income	$-7.2M	↓ 88.62%
Net Profit Margin	-2.06%	↑ 23.56%

	FY20	Y/Y Change
Revenue	$494.4M	↑ 40.72%
Net Income	$19.8M	↓ 373.97%
Net Profit Margin	4.01%	↑ 6.07%

	FY21	Y/Y Change
Revenue	$535.0M	↑ 8.23%
Net Income	$-58.4M	↓ 394.58%
Net Profit Margin	-10.91%	↓ 14.92%

	FY22	Y/Y Change
Revenue	$537.8M	↑ 0.53%
Net Income	$-92.5M	↑ 58.58%
Net Profit Margin	-17.2%	↓ 6.29%

	FY23	Y/Y Change
Revenue	$509.3M	↓ 5.3%
Net Income	$-207.0M	↑ 123.75%
Net Profit Margin	-40.65%	↓ 23.45%

	Q2 FY23	Q/Q Change
Revenue	$126.1M	↑ 3.17%
Net Income	$-57.4M	↑ 8.21%
Net Profit Margin	-45.55%	↓ 2.12%

	Q3 FY23	Q/Q Change
Revenue	$127.3M	↑ 1.01%
Net Income	$-49.5M	↓ 13.82%
Net Profit Margin	-38.87%	↑ 6.68%

	Q4 FY23	Q/Q Change
Revenue	$133.8M	↑ 5.08%
Net Income	$-47.1M	↓ 4.86%
Net Profit Margin	-35.19%	↑ 3.68%

	Q1 FY24	Q/Q Change
Revenue	$138.5M	↑ 3.53%
Net Income	$-38.8M	↓ 17.67%
Net Profit Margin	-27.98%	↑ 7.21%

	Q2 FY24	Q/Q Change
Revenue	$150.4M	↑ 8.56%
Net Income	$-33.4M	↓ 13.89%
Net Profit Margin	-22.2%	↑ 5.78%

	Q3 FY24	Q/Q Change
Revenue	$155.1M	↑ 3.15%
Net Income	$-30.6M	↓ 8.4%
Net Profit Margin	-19.71%	↑ 2.49%

	FY18	Y/Y Change
Profit	$168.0M	↑ 38.38%

	FY19	Y/Y Change
Profit	$262.7M	↑ 56.36%

	FY20	Y/Y Change
Profit	$387.9M	↑ 47.64%

	FY21	Y/Y Change
Profit	$420.2M	↑ 8.32%

	FY22	Y/Y Change
Profit	$423.0M	↑ 0.67%

	FY23	Y/Y Change
Profit	$381.1M	↓ 9.91%

	Q2 FY23	Q/Q Change
Profit	$92.0M	↓ 0.58%

	Q3 FY23	Q/Q Change
Profit	$95.2M	↑ 3.47%

	Q4 FY23	Q/Q Change
Profit	$101.2M	↑ 6.3%

	Q1 FY24	Q/Q Change
Profit	$104.8M	↑ 3.54%

	Q2 FY24	Q/Q Change
Profit	$115.7M	↑ 10.39%

	Q3 FY24	Q/Q Change
Profit	$119.7M	↑ 3.48%

	FY18	Y/Y Change
Operating Cash Flow	$-1.9M	↓ 94.37%
Investing Cash Flow	$-5.5M	↓ 163.66%
Financing Cash Flow	$69.4M	↑ 1242.28%

	FY19	Y/Y Change
Operating Cash Flow	$26.6M	↓ 1527.35%
Investing Cash Flow	$-51.7M	↑ 840.6%
Financing Cash Flow	$61.7M	↓ 11.08%

	FY20	Y/Y Change
Operating Cash Flow	$99.1M	↑ 272.46%
Investing Cash Flow	$-472.8M	↑ 815.18%
Financing Cash Flow	$440.2M	↑ 613.69%

	FY21	Y/Y Change
Operating Cash Flow	$82.8M	↓ 16.53%
Investing Cash Flow	$-144.8M	↓ 69.37%
Financing Cash Flow	$25.7M	↓ 94.16%

	FY22	Y/Y Change
Operating Cash Flow	$30.8M	↓ 62.8%
Investing Cash Flow	$-140.0M	↓ 3.37%
Financing Cash Flow	$15.5M	↓ 39.73%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-22.7M	↑ 35.93%
Investing Cash Flow	$-13.9M	↓ 116.89%
Financing Cash Flow	$7.5M	↑ 44.16%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-19.3M	↓ 15.05%
Investing Cash Flow	$17.3M	↓ 224.19%
Financing Cash Flow	$1.2M	↓ 84.39%

Novocure Technicals Summary

Sell

Neutral

Buy

Novocure is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Novocure (NVCR) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novocure Limited	-18.24%	19.73%	73.9%	-66.75%	-70.77%
Medtronic Plc	13.21%	13.06%	3.64%	-12.14%	-23.03%
Edwards Lifesciences Corp.	-0.19%	19.36%	-15.84%	-35.79%	-1.17%
Boston Scientific Corp.	14.52%	40.3%	59.02%	147.01%	142.39%
Stryker Corporation	9.08%	23.85%	14.4%	53.77%	84.88%
Abbott Laboratories	12.77%	17.77%	14.11%	-1.62%	46.94%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novocure Limited	NA	NA	-0.47	-1.3	-0.4	-0.08	NA	3.34
Medtronic Plc	28.13	28.13	1.56	5.45	0.08	0.04	0.03	38.29
Edwards Lifesciences Corp.	28.3	28.3	6.72	2.55	0.19	0.11	NA	16.18
Boston Scientific Corp.	85.16	85.16	1.86	2.46	0.09	0.05	NA	14.05
Stryker Corporation	50.25	50.25	2.73	13.51	0.19	0.07	0.01	52.86
Abbott Laboratories	16.74	16.74	2.32	5.15	0.15	0.06	0.02	22.94

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novocure Limited	Buy	$2.8B	-70.77%	NA	-25.93%
Medtronic Plc	Buy	$118.0B	-23.03%	28.13	12.06%
Edwards Lifesciences Corp.	Buy	$43.2B	-1.17%	28.3	65.86%
Boston Scientific Corp.	Buy	$151.9B	142.39%	85.16	11.26%
Stryker Corporation	Buy	$148.8B	84.88%	50.25	16.34%
Abbott Laboratories	Buy	$221.9B	46.94%	16.74	13.99%

Novocure Dividend announcements

Novocure Earnings
Novocure’s price-to-earnings ratio stands at None
Read More

About Novocure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Organization	Novocure
Employees	1453
CEO	Mr. William F. Doyle
Industry	Health Technology

Management People of Novocure

Name	Title
Mr. William F. Doyle	Executive Chairman
Ms. Ashley Cordova	Chief Executive Officer
Mr. Barak Ben Arye	General Counsel
Mr. Frank Leonard	Executive VP & President of Novocure Oncology
Prof. Yoram Palti M.D., Ph.D.	Founder & CTO
Mr. Christoph Brackmann	Chief Financial Officer
Mr. Mukund Paravasthu	Chief Operating Officer
Ms. Ingrid Goldberg	VP of Investor Relations
Mr. Michael Puri	Chief Human Resources Officer
Mr. Uri Weinberg M.D., Ph.D.	Chief Innovation Officer

Important FAQs about investing in NVCR Stock from India :

What is Novocure share price today?

Novocure share price today stands at $24.52, Open: $25.69 ; Previous Close: $25.51 ; High: $25.79 ; Low: $24.33 ; 52 Week High: $34.13 ; 52 Week Low: $11.70.

The stock opens at $25.69, after a previous close of $25.51. The stock reached a daily high of $25.79 and a low of $24.33, with a 52-week high of $34.13 and a 52-week low of $11.70.

Can Indians buy Novocure shares?

Yes, Indians can invest in the Novocure (NVCR) from India.

With INDmoney, you can buy Novocure at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Novocure at zero transaction cost.

How can I buy Novocure shares from India?

It is very easy to buy Novocure from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novocure (NVCR) be purchased?

Yes, you can buy fractional shares of Novocure with INDmoney app.

What are the documents required to start investing in Novocure stocks?

To start investing in Novocure, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.